Latest news with #Sensodyne
Daily News Egypt
3 days ago
- Business
- Daily News Egypt
Haleon captures over 20% market share in Egypt, locally manufactures 90% of product portfolio
Haleon, the global consumer health leader, has reinforced its footprint in Egypt following its demerger from GSK in July 2022. The company now holds over 20% of Egypt's consumer health market and manufactures approximately 90% of its flagship brands locally, according to Asif Alavi, General Manager for North Africa at Haleon. Speaking to Daily News Egypt, Alavi said that local production covers trusted household names such as Sensodyne, Parodontax, Panadol, Otrivin, and Voltaren Emulgel, underscoring Haleon's commitment to supply chain resilience and economic contribution through technology transfer and export capabilities. Egypt serves as a key regional base for exports to the Maghreb, Gulf countries, and Saudi Arabia. Alavi emphasized that local manufacturing has helped shield the company from global economic volatility, including inflation, currency fluctuations, and supply chain disruptions. 'Our strategy has significantly minimized exposure to global shocks, enabling us to maintain stability and accessibility in the Egyptian market,' he noted. Globally, Haleon is advancing its innovation pipeline, including a £130m investment in a new Global Oral Health Innovation Centre in Weybridge, UK, slated to open in 2027. The facility will support Haleon's category leadership in oral health and accelerate R&D for key brands like Sensodyne, which Alavi described as resilient due to its therapeutic value and strong dentist recommendations—even during economic downturns. Recognizing the price sensitivity in emerging markets, Haleon has adopted a multi-format, tiered pricing strategy to ensure broad accessibility. The company also champions self-care as a cornerstone of sustainable healthcare. Alavi cited research by the Global Self-Care Federation, which estimates self-care interventions have already delivered $119bn in global healthcare cost savings and $1.9trn in welfare gains—figures projected to rise to $179bn and $2.8trn, respectively. Looking ahead, Alavi reaffirmed Haleon's long-term vision in Egypt: 'We are committed to being a core contributor to the Egyptian healthcare ecosystem—by making everyday health more accessible, inclusive, and sustainable.'
Yahoo
26-05-2025
- Health
- Yahoo
Whitening without the pain: Sensodyne Clinical White gives Canadians a reason to smile
Sensodyne launches new premium Clinical White toothpaste to brighten Canadians' smiles in time for National Smile Day. Toronto, ON, May 26, 2025 (GLOBE NEWSWIRE) -- With National Smile Day around the corner, new research from Sensodyne, the #1 dentist-recommended brand for sensitive teeth, reveals that more than 80 per cent of Canadians want whiter teeth, but for many, sensitivity and cost are standing in the way. The recent survey in partnership with Harris Poll, showed that 40 per cent have resorted to TikTok trend alternatives like baking soda, activated charcoal and oil pulling to get the results they want, but these often come at a painful cost: nearly half (46 per cent) of users report increased sensitivity. Despite widespread awareness of dentist-administered whitening treatments, only a quarter (26 per cent) of Canadians have tried them, citing concerns around cost and tooth sensitivity. These findings underscore what Canadians are truly seeking: an affordable, convenient, and sensitivity-friendly way to restore brilliance to their pearly whites – especially in time for Smile Day. 'We know Canadians are eager to brighten their smiles, but too often, they're left choosing between results and comfort,' says Dr. Derek Chung, dentist and founder of Paste Dental. 'That's why innovations like Sensodyne Clinical White are game changers – they can deliver effective whitening while also protecting sensitive teeth. It's a safe way to achieve a radiant smile with less risk.' A brighter smile with no sensitivity According to the survey, sensitivity is the top barrier to whitening, with one in five Canadians reporting tooth sensitivity as the primary inconvenience when whitening. To turn these frowns upside down, Sensodyne has released its new, premium Clinical White toothpaste. Scientifically developed and clinically proven to whiten teeth up to two shades whiter,[1] Clinical White offers 24/7 sensitivity protection in an enamel-safe formula. Free from hydrogen peroxide, a trigger that may cause sensitivity, it lifts stains in hard-to-reach places, polishes for a smoother, shinier finish, and helps prevent future staining. With National Smile Day taking place this Saturday, May 31, Sensodyne's Clinical White arrives just in time offering an affordable, effective solution for those seeking a brighter smile without the pain. Gentle enough for daily use, it's the perfect companion for coffee lovers, red wine enthusiasts, and anyone who wants to smile with confidence, because people shouldn't have to choose between a white smile and a comfortable one. Now available at major retailers across the country. For more information visit [1] Compared with a regular toothpaste after 8 weeks of twice daily brushing. About Haleon Haleon (LSE / NYSE: HLN) is a global leader in consumer health, with a purpose to deliver better everyday health with humanity. Haleon's product portfolio spans six major categories: Oral Health; Vitamins, Minerals and Supplements (VMS); Pain Relief; Respiratory Health; Digestive Health; and Therapeutic Skin Health and Other. Built on trusted science, innovation and deep human understanding, Haleon Canada brands include Advil, Buckley's, Centrum, Emergen-C, Flonase, NeoCitran, Nexium, Polident, Robitussin, Sensodyne, TUMS, Voltaren and more. For more information on Haleon and its brands visit About Harris Poll The Harris Poll Canada is part of a full-service, global market research and consulting firm. We provide Canadian companies with accurate and trusted information to make key organizational decisions, avoid risk, and maximize growth. We are differentiated by decades of expertise in brand and reputation management, leadership from senior practitioners with over 20 years of experience, and our ability to activate results for meaningful impact. Visit CONTACT: Corporate Affairs, Haleon Canada Haleon Canada mediacanada@
Mid East Info
13-05-2025
- Business
- Mid East Info
Darśana Nair to lead Haleon Saudi Arabia as Kingdom accelerates health transformation under Vision 2030 - Middle East Business News and Information
Jeddah, Saudi Arabia: Haleon a global leader in consumer health, has appointed Darśana Nair as its new General Manager for Saudi Arabia. Her appointment reinforces the company's commitment to advancing everyday health in one of the region's most strategic growth markets. It underscores the importance of strong, inclusive, and locally embedded leadership in driving Haleon's next phase of impact across the Kingdom. Darśana takes on the role at a critical juncture as Saudi Arabia's Vision 2030 continues to drive significant transformation across the healthcare landscape — shifting focus toward prevention, innovation, and community-based care. With nearly two decades of experience across multinational healthcare and FMCG sectors, Darśana has worked with some of the world's biggest brands, including Mondelēz International, Arla Foods, PepsiCo, and Mars Wrigley. 'Saudi Arabia's bold aspirations for a healthier, more resilient future place healthcare at the core of national transformation. Vision 2030 invites purpose-led organizations to co-create lasting impact, and I'm proud to lead Haleon Saudi Arabia during this pivotal time. As our mission to advance everyday health aligns with the Kingdom's bold aspirations, we look forward to developing strong local partnerships, driving digital innovation, and empowering local talent. At Haleon, we are committed to delivering meaningful health outcomes by nurturing healthier habits and happier families – as we believe everyday health is a human right,' commented Nair. Based in Jeddah, she will lead Haleon's local operations, driving business growth, expanding local partnerships, and supporting the Kingdom's health priorities. About Haleon: Haleon (LSE / NYSE: HLN) is a global leader in consumer health, with a purpose to deliver better everyday health with humanity. Haleon's product portfolio spans five major categories – Oral Health, Pain Relief, Respiratory Health, Digestive Health and Other, and Vitamins, Minerals and Supplements (VMS). Its long-standing brands – such as Advil, Sensodyne, Panadol, Voltaren, Theraflu, Otrivin, Polident, parodontax and Centrum – are built on trusted science, innovation and deep human understanding.
Mid East Info
05-05-2025
- Business
- Mid East Info
Özlem Kaynak to lead Haleon's Middle East and Africa Operations as Region Prioritizes Self-Care - Middle East Business News and Information
Dubai, United Arab Emirates, May, 2025: Haleon, a global leader in consumer healthcare and home to brands including Panadol, Sensodyne, Parodontax, Voltaren, Otrivin, and Centrum, has named Özlem Kaynak as its new General Manager for the Middle East & Africa (MEA) Business Unit, effective May 1st. This appointment highlights Haleon's commitment to strengthening its leadership team and global market presence. Özlem's appointment comes at a time when the Middle East and Africa region is placing a growing emphasis on self-care and preventive health, in alignment with Haleon's commitment to delivering accessible health solutions to consumers. Based in Haleon's MEA regional hub office in Dubai, she will be responsible for driving the company's growth strategies and enhancing operations across more than 45 countries. These include Turkey, the Gulf & Near East (including the United Arab Emirates and adjoining countries), Pakistan, Kenya, South Africa, Egypt, and Saudi Arabia and others. Formerly overseeing the Central Eastern Europe (CEE) cluster including Romania, Hungary, Slovakia and Czech Republic. Özlem holds over 25 years of experience in the industry; her previous roles include positions at GSK Consumer Healthcare, Omega Pharma Perrigo, and NIVEA Beiersdorf, where she gained expertise in general management, marketing, and sales. 'I am thrilled to take on the responsibility of leading Haleon MEA — a strategically important region for driving global healthcare innovation,' commented Kaynak. 'I am particularly eager to collaborate with our partners and stakeholders to advance the health inclusivity agenda, ensuring that everyone feels empowered to prioritize their everyday health. I look forward to working with our teams as we support the region's wider healthcare ambitions and national well-being strategies.' Özlem's role will be focused on deepening market presence and unlocking equitable access to better everyday health for all. Her appointment reaffirms Haleon's efforts to increase the representation of women in leadership roles in healthcare. About Haleon: Haleon (LSE / NYSE: HLN) is a global leader in consumer health, with a purpose to deliver better everyday health with humanity. Haleon's product portfolio spans five major categories – Oral Health, Pain Relief, Respiratory Health, Digestive Health and Other, and Vitamins, Minerals and Supplements (VMS). Its long-standing brands – such as Advil, Sensodyne, Panadol, Voltaren, Theraflu, Otrivin, Polident, Parodontax and Centrum – are built on trusted science, innovation and deep human understanding.
Reuters
30-04-2025
- Business
- Reuters
Haleon first-quarter organic revenue growth beats estimates
April 30 (Reuters) - British consumer healthcare group Haleon's (HLN.L), opens new tab first-quarter organic revenue growth beat expectations on Wednesday as strong growth in oral health products offset weakness in respiratory health and digestive health products. Organic revenue for the three months ending March 31 grew 3.5%, and analysts were expecting a growth of 3.2%, according to a company-compiled consensus. Keep up with the latest medical breakthroughs and healthcare trends with the Reuters Health Rounds newsletter. Sign up here. Growing demand for Haleon's oral hygiene products, which includes Sensodyne and Parodontax, helped cushion the impact of lower revenue from its respiratory health and digestive health portfolio that include products like Otrivin and ENO. Haleon reaffirmed its 2025 guidance and said it continues to expect the macroeconomic environment to remain "challenging and uncertain".
